Posted On: 03/11/2015 12:30:51 PM
Post# of 30066
NEW YORK, March 10, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at 'The Physiopathology of Sigma-1 Receptors' symposium being held at the Nice Sophia Antipolis University in Nice, France. The scientific symposium takes place on March 17, 2015 and addresses the broad variety of potential applications of the sigma-1 receptor in neurodegenerative diseases, pain and cancer representing a new mode of action of functional proteins in the biological system. The neuroprotective action of the sigma-1 receptor and associated ligands may be explained by the novel mode of action of this unique molecular chaperone.
Dr. Missling's presentation is entitled 'Clinical trial design for Sigma-1 Receptor agonists' and will include an overview of the Phase 2a clinical trial design of ANAVEX 2-73 and ANAVEX PLUS, which is ongoing in Alzheimer's patients. The Company expects to release topline data in Q3 2015.
In addition, Dr. Missling's presentation will cover the validation of ANAVEX 2-73 as a potential platform drug for neurodegenerative diseases beyond Alzheimer's, including recently published, positive preclinical epilepsy data.
The Physiopathology of Sigma-1 Receptors symposium is being hosted by the Nice Sophia Antipolis University, The National Centre for Scientific Research (CNRS), the University of Montpellier and INSERM.
- See more at: http://globenewswire.com/news-release/2015/03...wZysL.dpuf
(OTCQX:AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at 'The Physiopathology of Sigma-1 Receptors' symposium being held at the Nice Sophia Antipolis University in Nice, France. The scientific symposium takes place on March 17, 2015 and addresses the broad variety of potential applications of the sigma-1 receptor in neurodegenerative diseases, pain and cancer representing a new mode of action of functional proteins in the biological system. The neuroprotective action of the sigma-1 receptor and associated ligands may be explained by the novel mode of action of this unique molecular chaperone. Dr. Missling's presentation is entitled 'Clinical trial design for Sigma-1 Receptor agonists' and will include an overview of the Phase 2a clinical trial design of ANAVEX 2-73 and ANAVEX PLUS, which is ongoing in Alzheimer's patients. The Company expects to release topline data in Q3 2015.
In addition, Dr. Missling's presentation will cover the validation of ANAVEX 2-73 as a potential platform drug for neurodegenerative diseases beyond Alzheimer's, including recently published, positive preclinical epilepsy data.
The Physiopathology of Sigma-1 Receptors symposium is being hosted by the Nice Sophia Antipolis University, The National Centre for Scientific Research (CNRS), the University of Montpellier and INSERM.
- See more at: http://globenewswire.com/news-release/2015/03...wZysL.dpuf
(0)
(0)
